Brokerages Set Korro Bio, Inc. (NASDAQ:KRRO) Price Target at $142.57

Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) has earned a consensus recommendation of "Buy" from the seven research firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $142.57.

KRRO has been the topic of a number of recent research reports. Oppenheimer assumed coverage on Korro Bio in a report on Friday, January 10th. They set an "outperform" rating and a $155.00 price objective on the stock. Royal Bank of Canada decreased their price target on Korro Bio from $105.00 to $95.00 and set an "outperform" rating on the stock in a research note on Wednesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $115.00 price target on shares of Korro Bio in a research report on Thursday.

Hedge Funds Weigh In On Korro Bio

A number of large investors have recently modified their holdings of the stock. Quest Partners LLC raised its holdings in Korro Bio by 172.1% during the 3rd quarter. Quest Partners LLC now owns 1,777 shares of the company's stock worth $59,000 after purchasing an additional 1,124 shares during the last quarter. Brown Brothers Harriman & Co. increased its stake in shares of Korro Bio by 251.0% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,854 shares of the company's stock valued at $95,000 after acquiring an additional 2,041 shares during the last quarter. BNP Paribas Financial Markets raised its position in shares of Korro Bio by 1,018.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 4,909 shares of the company's stock valued at $164,000 after acquiring an additional 4,470 shares during the period. MetLife Investment Management LLC boosted its stake in Korro Bio by 129.0% during the 3rd quarter. MetLife Investment Management LLC now owns 3,639 shares of the company's stock worth $122,000 after acquiring an additional 2,050 shares during the last quarter. Finally, State Street Corp boosted its position in shares of Korro Bio by 18.9% during the third quarter. State Street Corp now owns 118,765 shares of the company's stock worth $3,969,000 after purchasing an additional 18,877 shares in the last quarter. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Korro Bio Stock Up 8.5 %

KRRO stock traded up $1.86 during midday trading on Thursday, hitting $23.76. The stock had a trading volume of 105,877 shares, compared to its average volume of 87,840. Korro Bio has a 52 week low of $18.50 and a 52 week high of $98.00. The stock has a 50-day simple moving average of $29.88 and a 200 day simple moving average of $41.37.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($2.26) EPS for the quarter, topping analysts' consensus estimates of ($2.33) by $0.07. The business had revenue of $2.27 million for the quarter. Analysts predict that Korro Bio will post -9.52 earnings per share for the current year.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).